We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+4.49%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$9.36B
AUM Growth
-$287M
Cap. Flow
-$74.9M
Cap. Flow %
-0.8%
Top 10 Hldgs %
76.51%
Holding
102
New
8
Increased
20
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$42.6M
2
BCYC
Bicycle Therapeutics
BCYC
+$31.8M
3
GRAL
GRAIL Inc
GRAL
+$26.5M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$22M
5
RVMD icon
Revolution Medicines
RVMD
+$18.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$212M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$17.4M
3
TNGX icon
Tango Therapeutics
TNGX
+$5.78M
4
CRNX
Crinetics Pharmaceuticals
CRNX
+$5.31M
5
BMEA icon
Biomea Fusion
BMEA
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Miscellaneous 1.31%
3 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGS icon
76
Aligos Therapeutics
ALGS
$31.5M
$3.31M 0.04%
83,055
– –
PRME icon
77
Prime Medicine
PRME
$577M
$3M 0.03%
1,028,466
– –
TARA icon
78
Protara Therapeutics
TARA
$231M
$2.83M 0.03%
536,832
– –
ELVN icon
79
Enliven Therapeutics
ELVN
$3.99B
$2.58M 0.03%
114,833
– –
ARCT icon
80
Arcturus Therapeutics
ARCT
$435M
$2.57M 0.03%
151,329
– –
CMPX icon
81
Compass Therapeutics
CMPX
$353M
$2.26M 0.02%
1,557,630
– –
GBIO
82
DELISTED
Generation Bio
GBIO
$2.06M 0.02%
194,495
– –
HOOK
83
DELISTED
HOOKIPA Pharma
HOOK
$1.63M 0.02%
812,814
– –
MRSN
84
DELISTED
Mersana Therapeutics
MRSN
$1.55M 0.02%
43,445
– –
VTVT icon
85
vTv Therapeutics
VTVT
$124M
$1.34M 0.01%
97,314
– –
RCKT icon
86
Rocket Pharmaceuticals
RCKT
$377M
$1.22M 0.01%
+97,079
New +$1.46M
PTCT icon
87
PTC Therapeutics
PTCT
$5.55B
$921K 0.01%
+20,400
New +$873K
IPSC icon
88
Century Therapeutics
IPSC
$362M
$805K 0.01%
797,460
– –
PMVP icon
89
PMV Pharmaceuticals
PMVP
$78M
$486K 0.01%
322,024
– –
ACRV icon
90
Acrivon Therapeutics
ACRV
$84M
$318K ﹤0.01%
52,885
– –
FHTX icon
91
Foghorn Therapeutics
FHTX
$259M
$213K ﹤0.01%
45,027
– –
TYRA icon
92
Tyra Biosciences
TYRA
$1.5B
$147K ﹤0.01%
10,607
– –
SRZNW
93
DELISTED
Surrozen Inc Warrant
SRZNW
$17.8K ﹤0.01%
833,333
– –
ALEC icon
94
Alector
ALEC
$247M
– –
-927,264
Closed -$4.32M
JBIO
95
Jade Biosciences
JBIO
$1.16B
– –
-17,970
Closed -$1.31M
BCRX icon
96
BioCryst Pharmaceuticals
BCRX
$2.1B
– –
-75,778
Closed -$576K
CRNX
97
DELISTED
Crinetics Pharmaceuticals
CRNX
– –
-103,927
Closed -$5.31M
NAMS icon
98
NewAmsterdam Pharma
NAMS
$2.67B
– –
-96,711
Closed -$1.61M
PFE icon
99
Pfizer
PFE
$158B
– –
-35,000
Closed -$1.01M
TNGX icon
100
Tango Therapeutics
TNGX
$4.14B
– –
-750,000
Closed -$5.78M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Baker Bros. Advisors held 102 positions worth $9.36B, down 3% from $9.65B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q4 2024 filing shows 8 new, 20 increased, 5 reduced and 7 closed positions. Its largest new stake was GRAIL Inc: 1,630,125 shares worth $29.1M. The largest sale was BeOne Medicines Ltd, an estimated $212M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2024 buy was GRAIL Inc: 1,630,125 shares worth $29.1M.
  • Baker Bros. Advisors added most to Insmed in Q4 2024, an estimated $42.6M increase.
  • Baker Bros. Advisors's biggest Q4 2024 reduction was BeOne Medicines Ltd, cutting an estimated $212M.
  • Baker Bros. Advisors fully exited Tango Therapeutics in Q4 2024, selling an estimated $5.78M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $9.36B portfolio in Q4 2024.
  • Baker Bros. Advisors opened 8 new positions and closed 7 in Q4 2024.
  • Baker Bros. Advisors's portfolio value fell 3% quarter-over-quarter to $9.36B.

Based on Baker Bros. Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.